{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-056109","form_type":"8-K","ticker":"ONCO","cik":"0001782107","company_name":"Onconetix, Inc.","filed_at":"2026-05-14T00:35:37+00:00","discovered_at":"2026-05-14T10:10:00.383838+00:00","generated_at":"2026-05-14T10:15:24.130063+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Onconetix reports Q1 2026 progress: two Proclarix publications, PRIME study with Labcorp, European expansion","bullets":["Two peer-reviewed papers published: Schiess et al. in BMC Cancer (371 men) and Athanasiou et al. in Cancers (132 men) reinforce Proclarix performance in reducing unnecessary biopsies.","PRIME multi-center clinical study initiated with Labcorp; first participants enrolled, targeting up to 500 men for U.S. validation.","European commercial expansion: ~100 Proclarix tests performed in UK screening initiative in Q1 2026; collaboration partner identified in Turkey.","Proclarix is a CE-IVD certified blood test for identifying clinically significant prostate cancer, designed to reduce overdiagnosis."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-056109","json":"https://secwatch.observer/filing/0001213900-26-056109.json","markdown":"https://secwatch.observer/filing/0001213900-26-056109.md","text":"https://secwatch.observer/filing/0001213900-26-056109.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782107/000121390026056109/0001213900-26-056109-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782107/000121390026056109/ea0290739-8k_onconetix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T10:15:24.130063+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}